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Abstract 
Introduction/ Aim: Acquired immune deficiency syndrome (AIDS) 
is a disorder caused by human immune-deficiency virus. There are various 
life-long regimens that are currently used by HIV Patients to suppress and 
manage this disease. Tenofovir/Lamivudine/efavirenz (300/300/600mg) is 
one of the most available combinations that are frequently prescribed and 
dispensed to HIV patients. The aim of this clinical study is to evaluate the 
potential benefits of taking Moringa oleifera with 
Tenofovir/Lamivudine/efavirenz (TLE) on blood glucose and triglyceride 
level. Method: The study was designed as a Longitudinal Randomized 
Comparative Trial (LRCT) involving 140 HIV adult subjects (56 males, 84 
females) who have been on TLE combination for at least 6 months. They were 
recruited from a Teaching Hospital in Nigeria. On visit 0, blood samples of 
the subjects were taken for analysis. Moringa oleifera capsules (200mg) were 
administered by the subjects to be used beginning from the day of visit 0, 
through visit 1 (after four weeks) and 2 (after 12 weeks). Blood samples of 
European Scientific Journal July 2019 edition Vol.15, No.21 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
281 
subjects were collected at each visit (visit 1 and 2) and analyzed for glucose 
and triglyceride level. Result: The analysis of each visits were compared and 
it was observed that there was no significant reduction in blood glucose level 
(P<0.01) of subjects in visit 1 compared to visit 0. There was significant 
improvement in blood glucose level (P<0.01) in visit 2 compared to visit 0, 
when subjects received tenofovir/Lamivudine/Efavirenz (TLE) combination 
without Moringa oleifera. It was also observed that there was no significant 
difference in the blood triglyceride level (P<0.01) of subjects in visit 1 and 
visit 2, compared to visit 0. Conclusion: Results from the study revealed that 
Moringa oleifera may be useful in improving blood level of glucose of patients 
administering TLE combination with no observable effects on triglyceride 
level of HIV patients on the drug regimen. 
 
Keywords: Moringa oleifera, Blood, Glucose, Tenofovir, Triglyceride 
 
Introduction 
There was sudden rise of Kaposi Sarcoma in 1981, observed among 
young homosexuals (CDC, 1982) with infrequent lung Pneumocystis Carinii 
Pneumonia (PCP) discovered among homosexual men and drug abusers in that 
same period (Masur et al., 1981; Gallo et al., 1984) The initiator for these 
conditions was “Acquired Immunodeficiency Syndrome (AIDS)” which was 
the “terminal stage infection” by a retrovirus called the Human 
Immunodeficiency Virus (HIV) (NIH, 2010; Leone et al., 2015). HIV is of 
two types namely; HIV 1 and HIV 2. They are two different viruses. HIV 1 
accounts for 95% of all infectious cases worldwide. HIV 2 is mainly seen in a 
few West African countries. Though HIV 2 progresses slowly than HIV 1 
some antiretrovirals such as nevirapine and efavirens do not work against HIV 
2. The management of HIV/AIDS normally includes the use of 
multiple antiretroviral drugs in an attempt to control HIV infection. 
Antiretroviral formulations blocks HIV at certain stages of the viral “life 
cycle”(Estrella, Mantaring and David, 2000). Antiretroviral therapy treats 
HIV by suppressing the virus activity in the body. For most people who take 
them, these medications are very effective at keeping HIV under control. 
Treatment helps to improve quality of life, and it can ensure that a person 
with HIV has a similar life expectancy to a person without the virus. 
Suppressing viral activity results in a low viral load and a reduced risk of 
developing other illnesses. According to the United States Department of 
Health and Human Services (HHS), the main goal of antiretroviral therapy is 
to reduce a person's viral load to undetectable levels. The drugs can have 
serious side-effects which can lead to harm as well as keep patients from 
taking their medications regularly. This effects include lactic acidosis, 
liver steatosis, peripheral neuropathy, myopathy, lipoatrophylipodystrophy, 
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elevated triglycerides and elevated risk of heart attack.  
Moringa oleifera Lam (Moringaceae) is a highly valued plant, distributed in 
many countries of the tropics and subtropics. It has an impressive range of 
medicinal uses with high nutritional value. Different parts of this plant contain 
a profile of important minerals, and are a good source of protein, vitamins, 
beta-carotene, amino acids and various phenolics. The Moringa leaf are 
prepared for consumption either fresh, dried, or as extract of an aqueous 
solution (Siddhuraju and Becker, 2003; Chukwuebuka, 2015; Von 
Maydell,1986). Some populations consume it in their daily diet, whereas 
others use as a nutritional supplement and for medicinal purposes, mainly for 
diabetes. Common ailments such as malaria, typhoid fever, swellings, cuts, 
hypertension and diabetes are treated with the leaves (Siddhuraju and Becker, 
2003). They are also used to bring about milk production in lactating women 
(Olsen, 1987; Calza, Manfredi, Chiodo, 2004b; Calza,, Manfredi, Chiodo, 
2004a), sediment impurities of water (Anwar et al., 2007), detoxifies the 
system of free radicals (Ete et al., 2004; Kumar and Mandapaka, 2013), 
improves immunity (to manage HIV/AIDS and treat related symptoms). The 
aim of this study is to evaluate the clinical effect of taking Moringa oleifera 
with Tenofovir/Lamivudine/efavirenz (300/300/600mg) (TLE) regimen on 
blood glucose and triglyceride level.    
 
Materials and Method 
The study designed was a Longitudinal “Randomized Comparative 
Trial” (LRCT) as applicable in clinical investigation involving two or more 
patient treatment groups, over a time frame. This study is designed in line with 
a part of the FDA (Food and Drug Administration)/WHO Phases during 
“randomized controlled clinical trials” (RCCT) of drugs. However, details 
about the application of RCCT have been clarified by FDA/WHO which made 
the purpose of such investigation explicit; stating that it was designed to affirm 
and or set aside hypothetical clinical claims (Junod and Beaver, 2013) of 
administrable substances. Groups were analyzed in 3 phases as baseline 
(commencement) 4weeks follow-up and 12 weeks post commencement of 
supplements (conclusion of administration). 
 
Recruitment procedure 
Subjects were recruited at the out-patient department of a Teaching 
Hospital HIV-clinic. Prospective participants were officially and properly 
informed prior to the exercise, doubts were cleared and benefits x-rayed to the 
patients. The Longitudinal Randomized Comparative Trial (LRCT) was 
employed and used. 
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Procedure 
The study was designed as a Longitudinal Randomized Comparative 
Trial (LRCT) involving a total of 140 HIV adult subjects (56 males, 84 
females) who have been on TLE combination for at least 6 months. Subjects 
were categorized into groups as underweight, normal weight, over weight and 
obese. On visit 0, blood samples of the subjects already on TLE regimen 
(without moringa or any supplements) for at least 6 month were taken for 
analysis. Moringa oleifera capsules (200mg) were given to each subject to be 
taken from commencement (baseline) to 12 weeks post commencement of 
study. Blood samples of subjects were collected at each visit (visit 1 and 2) 
and analyzed for glucose and triglyceride level.  
 
Data collection 
Anthropometric parameters (weight and height) and blood samples 
were determined for eligible patients (participants) distributed into the various 
categories; after duly signed consent forms were retrieved. Blood samples 
were analyzed at the UPTH Hematology research lab within the hospital 
premises. 
 
Blood Sample 
Analysis of samples was done at the hematology laboratory of the 
“University of Port Harcourt Teaching Hospital” (UPTH), Rivers state, 
Nigeria. “Computerized clinical chemistry analyzer” (VS10) (Vitro Scient) 
operating with the principle guided by “Beer-lambert’s law” was used to 
determine concentration of biochemical parameters under study. 
Parameters as analysed were; 
1. Triglyceride (TG; 0.9-1.03mmol/l); 1000ul of reagent as well as 10ul 
of serum were incubated for four (4) minutes at room temperature, at 
a wavelength of 460-540nm. 
2. Random Plasma Glucose (RPG; 4.4-7.8 mmol/l): Determined using a 
glucometer. The routine screening processes were undertaken by the 
physician. 
 
Data analysis 
Data was presented in tables using SPSS (IBM® version 23) and 
MATLAB (version 17). Descriptive statistics was used to express variable 
characteristics (with continuous data stated as mean (S.D) while categorical 
data as frequency [%]). Dunnette T3 Post Hoc test of multiple comparisons 
was used to compare means, while binary logistic regression was used to 
predict factors contributing to the changes in variables. Variable interactions 
were tested at 95% confidence level; with P≤0.05 taken to be significant. 
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Ethical consideration 
Ethical approval 
Ethical approval was granted by the “University of Port Harcourt 
Research Ethics Committee”referenced as UPH/R&D/REC/--- 
Patient consent 
In line with the ethical requirement documented by Didia (2008), the 
following ethical issues were considered while carrying out the study: 
i. Beneficence, (the duty to do good, and with due consideration of 
the best interests of the subjects). 
ii. Non-maleficence, (the obligation of avoidance of harm to the 
subjects; when possible). 
iii. Respect for persons, (Giving the deserved respect to all subjects). 
iv. Justice and confidentiality (ensure fairness and unconditional 
privacy protection) 
Individual who did not want to participate were not compelled nor forced. 
Volunteer subjects gave informed consent prior to the experiment. This was 
done following the Revised “Council for International Organization of 
Medical Sciences (CIOMS) International Ethical Guidelines, Utrecht, 
Netherlands, June 2016”. However, all relevant statutory requirements were 
followed to the later and where necessary. 
 
Result 
Glucose and triglyceride level of ART subject taking TLE on visit day 0 
Underweight subjects were found to be 6 subjects, normal weight were 
76 subjects, overweight were 44 subjects while obese were found to be 14 
subjects (table 1).  
Effect of Moringa oleifera on ART patient taking TLE on visit day 1 
There was significant differences (P<0.001) observed in mean values 
between TLE/Moringa (visit 1) and TLE/Non Moringa (visit 1) in the level of 
serum glucose of the subjects. Also, there was no significant difference 
between TLE/Moringa (visit 1) and TLE/Non Moringa (visit 1) in the level of 
serum triglyceride of the subjects (table 2,3,4 and 5) 
Effect of Moringa oleifera on ART patient taking TLE on visit day 2 
The differences observed in mean values between TLE/Moringa (visit 
2) and TLE/Non Moringa (visit 0) were statistically significant (P<0.001) for 
the subjects used, while there was no significant differences (P<0.001) 
between TDF/Moringa (visit 2) and TDF/Non Moringa (visit 0) in the level of 
serum triglyceride (table 2, 3, 4 and 6). 
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Table 1: The descriptive characteristics and test of mean differences of glucose and 
triglyceride level of the HIV patients on tenofovir based ART at Visit 0 (Baseline) 
 Descriptive statistics T-test of mean difference 
PARAMETERS Sex N Mean±S.D S.E t-value P-value Inf 
GLU (mmol/l) 
 
Male 56 7.86±2.35 0.31 
3.010 0.003 S 
Female 84 6.74±2.00 0.21 
Total 140 7.18±2.21     
 
TG (mmol/l) 
 
Male 56 1.43±0.49 0.07 2.305 0.023 S 
 Female 84 1.24±0.47 0.05    
 Total 140 1.32±0.48     
 
Table 2:Post Hoc (Dunnette T3) multiple comparison of the metabolic profile of HIV male 
patients on TLE taking moringa supplement across the various visits 
Note: GLU=Serum glucose, TG=Triglyceride,TLE/M= Tenofovir/Lamivudine/efavirenz 
with moringa, TDF/NM= Tenofovir/Lamivudine/efavirenz without moringa 
S.D=Standard deviation, S.E=Standard error of mean, Min=Minimum, Max=Maximum, 
*^ꞋPost Hoc (Dunntte T3) multiple comparison (* Visit 0≠Visit 1, ^ Visit 0≠Visit 2, Ꞌ Visit 
1≠Visit 2; *^ꞋP<0.05). 
 
Table 3:Post Hoc (Dunnette T3) multiple comparison of the metabolic profile of HIV (female) 
patients on TLE taking moringa supplement across the various visits 
Parameters Visits Mean±S.D Min Max S.E 
95% C.I for Mean 
Lower 
Bound 
Upper 
Bound 
GLU (mmol/l) 
Visit 0 6.74±2.00*^ 4.09 13.30 0.22 6.31 7.18 
Visit 1 6.09±1.35 3.99 11.80 0.15 5.80 6.38 
Visit 2 6.06±0.73 5.01 8.25 0.08 5.90 6.22 
Total 6.30±1.48 3.99 13.30 0.09 6.11 6.48 
Parameters Visits Mean±S.D Min Max S.E 
95% C.I for Mean 
Lower 
Bound 
Upper 
Bound 
GLU (mmol/l) 
Visit 0 7.86±2.35*^ 4.22 18.00 0.31 7.23 8.49 
Visit 1 6.20±1.03Ꞌ 4.10 8.71 0.14 5.92 6.47 
Visit 2 5.59±0.80 4.08 8.05 0.11 5.38 5.81 
Total 6.55±1.82 4.08 18.00 0.14 6.27 6.83 
T.G (mmol/l) 
Visit 0 1.43±0.49*^ 0.58 2.83 0.07 1.30 1.56 
Visit 1 1.25±0.40Ꞌ 0.42 2.17 0.05 1.14 1.35 
Visit 2 1.09±0.55 0.02 3.25 0.07 0.94 1.23 
Total 1.26±0.50 0.02 3.25 0.04 1.18 1.33 
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T.G (mmol/l) 
Visit 0 1.24±0.47 0.30 2.30 0.05 1.14 1.35 
Visit 1 1.27±0.37 0.24 2.21 0.04 1.19 1.35 
Visit 2 1.15±0.47 0.23 3.18 0.05 1.05 1.25 
Total 1.22±0.44 0.23 3.18 0.03 1.17 1.28 
 
Table 4: The descriptive characteristics of metabolic profile of the HIV patients on 
tenofovir with Moringa (TLE/M) and tenofovir not on Moringa (TLE/NM) at Visit 0 
(Baseline) 
GROUPS  
GLU 
(mmol/l) 
T.G 
(mmol/l) 
TLE/M 
(N=56) 
Mean±S.D 7.86±2.35 1.43±0.49 
S.E 0.31 0.07 
Min 4.22 0.58 
Max 18 2.83 
TLE/FM 
(N=84) 
Mean±S.D 6.74±2.00 1.24±0.47 
S.E 0.22 0.05 
Min 4.09 0.3 
Max 13.3 2.3 
Total 
(N=140) 
Mean±S.D 7.19±2.21 1.32±0.48 
S.E 0.19 0.04 
Min 4.09 0.3 
Max 18 2.83 
 
Table 5: The descriptive characteristics of metabolic profile of the HIV patients on tenofovir 
with Moringa (TLE/M) and tenofovir alone (TLE/NM) at Visit 1 (4 weeks of administration) 
GROUPS  
GLU 
(mmol/l) 
T.G 
(mmol/l) 
TLE/M 
(N=56) 
Mean±S.D 6.20±1.03 1.25±0.40 
 S.E 0.14 0.05 
 Range (Min – Max) 4.1 - 8.71 0.42 - 2.17 
    
TLE/FM 
(=84) 
Mean±S.D 6.09±1.35 1.27±0.37 
 
S.E 0.15 0.04 
Range (Min– Max) 3.99 - 11.8 0.24 - 2.21 
   
Total 
(N=140) 
Mean±S.D 6.13±1.23 1.26±0.38 
S.E 0.1 0.03 
Range(Min – Max) 3.99 - 11.8 0.24 - 2.21 
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Table 6: The descriptive characteristics of metabolic profile of the HIV patients on 
tenofovir with Monringa (TLE/M) and tenofovir alone (TDF/NM) at Visit 2 (12 weeks of 
administration) 
GROUPS  
GLU 
(mmol/l) 
T.G 
(mmol/l) 
TLE/M 
(N=56) 
Mean±S.D 5.59±0.11 1.09±0.55 
S.E 0.11 0.07 
Range (Min – Max) 4.08 – 8.05 0.02 – 3.25 
   
TLE/FM 
(N=84) 
Mean±S.D 6.06±0.73 1.15±0.47 
S.E 0.10 0.05 
Range (Min– Max) 4.18 - 8.25 0.23 - 3.18 
   
Total 
(N=140) 
Mean±S.D 5.87±0.79 1.13±0.50 
S.E 0.07 0.04 
Range(Min – Max) 4.08 - 8.25 0.02 - 3.25 
   
 
Figure 4.2: BMI associated glucose classification and distribution at Visit 0 (Baseline) 
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Figure : BMI associated triglyceride classification and distribution at Visit 0 (Baseline) 
 
Discussion 
Although the study was abinitio designed to investigate the effect of 
M. oleifera supplementation on TLE dependent HIV patients. However, 
various reports of ARV therapy associated metabolic abnormalities (Kar, 
Choudhary, and Bandyopadhyay, 2003; Meraiyebu, Ogunwole, and 
Izuchukwu, 2014; Ndong, Uehara, Katsumata, and Suzuki, 2007) informed 
this investigation. Also the increased prevalence of these abnormalities 
necessitated the evaluation of the relationship TDF based regimen has with 
abnormal presentation of selected metabolic profile. It should be known that 
HIV patients in the current study have been on TDF ART for at least six 
months and there are strong suggestions that the type of ARV-T, duration and 
application is significantly associated with “the severity of metabolic 
syndromes” (Mbikay, 2012; Moore and Chaisson, 1999; Eisinger, 
Dieffenbach and Fauci, 2019; Fauci and Folkers, 2012)). Moringa has been 
reported to have antioxidant and immune boosting effects (Deeks, Lewin and 
Havlir, 2013; Walensky et al., 2013).  
Blood glucose level difference was mostly affected by the Moringa at 
Visit 2 (12 weeks after administration) with values and proportion of the 
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subjects being closer to normal when compared to the baseline data. Studies 
have suggested that Moringa contains niazirin (=4-(α-L-rhamnopyranosyl) 
phenylacetonitrile, niazicin (=methyl N-{4-[(4′-O-acetyl-α-L- 
rhamnopyranosyl) benzyl]}thiocarbamate, methyl N-{4- [(α-
Lrhamnopyranosyl) benzyl]} carbamate, and methyl N-{4-[(4′-O-acetyl-α-
Lrhamnopyranosyl) benzyl]} carbamate (Horn, 2012; Priyanka et al., 2015; 
Beardsley, 1998; Thompson et al., 2012) and the combination of the 
compound at specific yield values at 100 ppm can significantly stimulated 
insulin release which increase glucose uptake and significantly reduce the free 
glucose molecules in circulation (Beardsley, 1998; Thompson et al., 2012). 
The time and effect on M.oleifera on ART dependent HIV patients may differ 
owing to the counteracting effect of both HIV and the ART on the progresses 
action of Moringa; However, Kar et al. (2012) and Meraiyebu et al. (2005) 
established that after a week administration of single doses of Moringa leaves 
extract in increased dosage (250, 300, 400mg.kg-1 BW) there was 1/2 
reduction in glucose level diabetic rats. Using rat models (Meraiyebu et al. 
2005; Austin, Hokanson, Edwards, 1998; Sarwar et al 2007; Hulley, 
Rosenman, Bawol, Brand, 1980) also established that in normoglycaemic 
conditions Moringa activities may not be quite noticeable when compared 
glucose uptake compromised rats.  The reason for such activities have been 
associated with certain compounds like isothiocyanates found in Moringa 
decreases the effect on insulin resistance and hepatic gluconeogenesis. Also 
Phenolic acids and flavanoids, have been reported to induce glucose 
homeostasis by affecting on some cellular signaling pathways in tissues 
known to undertake gluconeogenesis (Consensus Conference, 1984; NIH, 
1983). 
The study showed there was no significant reduction in the level of 
triglyceride in visit 1 and 2 when compared to parameter measured in visit 0. 
A long-standing association exists between elevated triglyceride levels and 
cardiovascular disease (CVD) (Carroll et al., 2005). Hypertriglyceridemia that 
result from either increased production or decreased catabolism of 
triglyceride-rich lipoproteins (TRLs; ie, chylomicrons and very low-density 
lipoproteins) directly influences LDL and HDL composition and metabolism 
and artherogenicity (Flegal, Carroll, Ogden, Johnson, 2002; Oyepata, Jude and 
Opeyemi, 2018; Daniels et al 2005; Johnson et al., 2009; NCEP, 2001). Increase 
level of triglyceride possibly induced by taking tenofovir, lamivudine and 
efivarenz drugs was not reduced or controlled by moringa. This is an 
indication that moringa plant may not have effect in reducing or reversing 
cardiovascular effect induced by hyperglyceridenemia. 
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Conclusion 
Results from the study suggests that Moringa oleifera alongside other 
benefits, may be useful in controlling blood glucose level of patients taking 
tenofovir/lamivudine/efavirenz and maybe other tenofovir base regimen, but 
may be of little to no benefit in reducing serum level of triglyceride which is 
usually triggered by the use of tenofovir regime. 
 
Acknowledgement 
The authors of this work wishes to thank UNIPORT, UPTH and everyone 
involved in the success of this clinical research work.  
 
References: 
1. Austin MA, Hokanson JE, Edwards KL. (1998). Hypertriglyceridemia 
as a cardiovascular risk factor. Am J Cardiol. 81: 7B–12B. Beardsley 
T (1998). Coping with HIV's ethical dilemmas. Scientific 
American. 279(1): 106–112 
2. Calza, L., Manfredi R, Chiodo F. (2004b). Lipodystrophy and lipid 
metabolism alterations in HIV-infected patients receiving highly 
active antiretroviral therapy (HAART). Recenti Progressi in Medicina, 
95(5): 265-75. 
3. Calza, L., Manfredi, R., and Chiodo, F. (2004a). Dyslipidaemia 
associated with antiretroviral therapy in HIV-infected patients. Journal 
of Antimicrobial Chemotherapy, 53(1): 10-4. 
4. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, 
Grundy SM, Johnson CL. (2005). Trends in serum lipids and 
lipoproteins of adults, 1960–2002. 294: 1773–1781.  
5. Center for Disease Control (CDC). (1982). Persistent, generalized 
lymphadenopathy among homosexual males. Morbidity and Mortality 
Weekly Report, 31:249-52. 
6. Chukwuebuka, E. (2015). Moringa oleifera “The Mother’s Best 
Friend”. International Journal of Nutrition and Food Sciences, 4(6): 
624-630. 
7. Consensus Conference: treatment of 
hypertriglyceridemia. JAMA. (1984). 251: 1196–1200.  
8. Daniels SR, Arnett DK, Eckel RH, Gidding SS, Hayman LL, 
Kumanyika S, Robinson TN, Scott BJ, St Jeor S, Williams CL. (2005). 
Overweight in children and adolescents: pathophysiology, 
consequences, prevention, and treatment. 111: 1999–2012.  
9.  Deeks SG, Lewin SR, Havlir DV (2013). The end of AIDS: HIV 
infection as a chronic disease. Lancet. 382 (9903): 1525–33. 
European Scientific Journal July 2019 edition Vol.15, No.21 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
291 
10.  Eisinger RW, Dieffenbach CW, Fauci AS (2019). "HIV Viral Load 
and Transmissibility of HIV Infection: Undetectable Equals 
Untransmittable". JAMA. 321 (5): 451–452.   
11. Estrella MC., Mantaring JBV., and David, GZ. (2000). A double blind, 
randomised controlled trial on the use of malunggay (Moringa 
oleifera) for augmentation of the volume of breastmilk among non-
nursing mothers of preterm infants. Philipp Journal of Pediatrics, 49: 
3–6. 
12. Ete T, Ranabir S, Thongam N, Ningthoujam B, Rajkumar N, and 
Thongam B. (2014). Metabolic abnormalities in human 
immunodeficiency virus patients with protease inhibitor-based 
therapy. Indian Journal of Sexually Transmitted Diseases, 35(2): 100–
103. 
13. Executive Summary of The Third Report of The National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, 
And Treatment of High Blood Cholesterol In Adults (Adult Treatment 
Panel III). (2001). 285: 2486–2497.  
14. Fauci AS, Folkers GK (July 2012). "Toward an AIDS-free 
generation". JAMA. 308 (4): 343–4.  
15. Flegal KM, Carroll MD, Ogden CL, Johnson CL. (2002). Prevalence 
and trends in obesity among US adults, 1999–2000. 288: 1723–1727. 
16. Gallo, RC, Salahuddin SZ, Popovic M., Shearer GM, Kaplan M, 
Haynes BF. (1984). Frequent detection and isolation of cytopathic 
retroviruses (HTLV-III) from patients with AIDS and at risk for 
AIDS. Science, 224: 500–503. 
17. Horn T (2012). "Activists Protest Stribild's $28,500 Price Tag". AIDS. 
Meds. Retrieved 2014-04-11. 
18.  Hulley SB, Rosenman RH, Bawol RD, Brand RJ. (1980). 
Epidemiology as a guide to clinical decisions: the association between 
triglyceride and coronary heart disease. N Engl J Med. 302: 1383–
1389.  
19. Perk G, De Backer H and Gohlke J. (2012). “European guidelines on 
cardiovascular disease prevention in clinical practice,” European 
Heart Journal, vol. 33, no. 13, pp. 1635–1701. View at Publisher.  
20. Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, 
Sacks F, Steffen LM, Wylie-Rosett J. (2009). On behalf of American 
Heart Association Nutrition Committee of the Council on Nutrition, 
Physical Activity, and Metabolism and the Council on Epidemiology 
and Prevention. Dietary sugars intake and cardiovascular health: a 
scientific statement from the American Heart Association. 120: 1011–
1020.  
European Scientific Journal July 2019 edition Vol.15, No.21 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
292 
21. Kar A, Choudhary, BK, and Bandyopadhyay NG. (2003). 
Comparative evaluation of hypoglycemic activity of some Indian 
medicinal plants in alloxan diabetic rats. Journal of 
Ethnopharmacology, 84:105-108. 
22. Kumar, KP, and Mandapaka, RT. (2013). Effect of Moringa oleifera 
on blood glucose, LDL levels in types ii diabetic obese people. 
Innovative Journal of Medical and Health Science 3: 23 - 25. 
23.  LaRosa JC, Grundy SM, Waters DD. (2005). “Intensive lipid lowering 
with atorvastatin in patients with stable coronary disease,” The New 
England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435. 
24. Leone, A., Spada, A., Battezzati, A., Schiraldi, A., Aristil, J., and 
Bertoli, S. (2015). Cultivation, Genetic, Ethnopharmacology, 
Phytochemistry and Pharmacology of Moringa oleifera Leaves: An 
Overview. International Journal of Molecular Sciences, 16(6): 12791–
835. 
25. Masur, H., Michelis, MA, Greene, JB., Onorato, I., Stouwe, RA, 
Holzman, RS, Wormser, G., Brettman, L. (1981). An outbreak of 
community-acquired Pneumocystis carinii pneumonia: Initial 
manifestation of cellular immune dysfunction. North England Journal 
of Medicine, 305: 1431–1438. 
26. Mbikay, M. (2012). Therapeutic Potential of Moringa oleifera Leaves 
in Chronic Hyperglycemia and Dyslipidemia: A Review. Frontiers in 
Pharmacology, 3, 24. 
27. Meraiyebu, A., Ogunwole, E., and Izuchukwu, NS. (2014). Effects of 
Aqueous Extract of Moringa oleifera Seeds on Alloxan Induced 
Hyperglycemia. Basic Sciences of Medicine, 3(3): 37-42. 
28. Moore RD, Chaisson RE (1999). Natural history of HIV infection in 
the era of combination antiretroviral therapy. AIDS. 13 (14): 1933–
42.  
29. National Institutes of Health (NIH). (2010). The relationship between 
the Human Immunodeficiency Virus and the Acquired 
Immunodeficiency Syndrome: Understanding and Cause. Health & 
Research Topics. Available at http://www.niaid.nih.gov/topics/ 
hivaids/understanding/howhivcausesaids/pages/relationshiphivaids.as
px  
30. Ndong M., Uehara M., Katsumata, S., and Suzuki, K. (2007). Effects 
of Oral Administration of Moringa oleifera Lam on Glucose Tolerance 
in Goto-Kakizaki and Wistar Rats. Journal of Clinical Biochemistry 
and Nutrition, 40(3):229-33. 
31. NIH Consensus Development Panel on Triglyceride, High-Density 
Lipoprotein, and Coronary Heart Disease. (1993). Consensus 
European Scientific Journal July 2019 edition Vol.15, No.21 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
293 
Conference: triglyceride, high-density lipoprotein, and coronary heart 
disease. 269: 505–510.  
32. Olsen, A. (1987) Low technology water purification by bentonite clay 
and Moringa oleifera seed flocculation as performed in Sudanese 
villages. Effects on Schistosoma mansoni cercariae. Water Research, 
21(5): 517-522. 
33. Oyepata SJ, Jude EO, Opeyemi TJ. (2018). Hepatoprotective activity 
of extract of Homalium Letestui stem against carbon tetrachloride-
induced liver injury. Advanced Herbal Medicine. 3(4): 1-11. 
34.  Pedersen TR, Faergeman O., Kastelein JJP. (2005). “High-dose 
atorvastatin vs usual-dose simvastatin for secondary prevention after 
myocardial infarction: the IDEAL study: a randomized controlled 
trial,” Journal of the American Medical Association, vol. 294, no. 19, 
pp. 2437–2445.  
35. Priyanka D, Rajesh KS, VS and Pankaj J. (2015). Immunomodulatory 
Activity of Moringa oleifera in Albino Rats. Journal of Animal 
Research: v.5 n.2, p. 277-281.  
36. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, 
Bingham S, Boekholdt SM, Khaw KT, Gudnason V. (2007). 
Triglycerides and the risk of coronary heart disease: 10,158 incident 
cases among 262,525 participants in 29 Western prospective 
studies. 115: 450–458. 
37. Siddhuraju, P., and Becker, K. (2003). Antioxidant properties of 
various solvent extracts of total phenolic constituents from three 
different agroclimatic origins of drumstick tree (Moringa oleifera 
Lam.) leaves. Journal of Agricultural and Food Chemistry, 51: 2144-
2155 
38. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P. (July 
2012). Antiretroviral treatment of adult HIV infection: 2012 
recommendations of the International Antiviral Society-USA 
panel. JAMA. 308  
39. Von Maydell, HJ. (1986). Trees and Shrubs of Sahel, Their 
Characterization and Uses. Deutsche Gesellschaft fur Technische 
Zusammenarbeit, Germany: Eschborn, 334–337. 
40. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel 
AD. (October 2013). "Cost-effectiveness of HIV treatment as 
prevention in serodiscordant couples". The New England Journal of 
Medicine. 369 (18): 1715–25. 
 
 
